Cadonilimab (AK104) Clinical Trials
6 recruitingDrug
Phase 24Phase 32Phase 11
Showing 1–6 of 6 trials
Recruiting
Phase 3
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
MSI-H/dMMR Colorectal CancerResectable Colon Cancer
Akeso386 enrolled1 locationNCT07412613
Recruiting
Phase 2
Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Akeso90 enrolled1 locationNCT07263919
Recruiting
Phase 1Phase 2
Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
Leptomeningeal Metastasis
Guangzhou Medical University36 enrolled1 locationNCT06762080
Recruiting
Phase 3
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
NSCLC (Non-small Cell Lung Cancer)
Akeso560 enrolled1 locationNCT06617416
Recruiting
Phase 2
SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)
Breast Cancer
Hubei Cancer Hospital51 enrolled1 locationNCT06401005
Recruiting
Phase 2
A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy
Non-small Cell Lung Cancer
Xin-Hua Xu48 enrolled1 locationNCT06467500